Literature DB >> 22847601

Prognostic value of Twist and E-cadherin in patients with osteosarcoma.

Ke Yin1, Qiande Liao, Hongbo He, Da Zhong.   

Abstract

Twist, a basic helix-loop-helix transcription factor, and E-cadherin are both correlated with the metastatic progression of several types of cancer. However, it is currently unknown whether their activations have relevance to the progression of osteosarcoma. The purpose of the present study was to investigate the clinicopathological and prognostic value of Twist and E-cadherin in osteosarcoma. Twist and E-cadherin expressions were determined by immunohistochemistry. Patient survival rates were determined by Kaplan-Meier method and log-rank test. Cox regression was adopted for multivariate analysis of prognostic factors. The positive rates of Twist and E-cadherin in 107 osteosarcoma specimens were 31.8 % (34/107) and 20.6 % (22/107), respectively. Twist expression was significantly correlated with that of E-cadherin (r = -0.209, P = 0.031). The positive expression of Twist and E-cadherin was significantly associated with metastasis in 107 osteosarcoma specimens (both P < 0.05). Patients with positive Twist expression had significantly poorer overall survival (OS; P < 0.05) and disease-free survival (DFS, P < 0.05) when compared with patients with the negative expression of Twist. Patients with positive expression of E-cadherin had significantly poorer OS (P < 0.05) when compared with patients with negative E-cadherin expression, but not a significantly poorer DFS (P = 0.081). On multivariate analysis, Twist expression and age were found to be independent prognostic factors for OS (both P < 0.05) and DFS (both P < 0.05). Our results suggest that Twist was expressed significantly more and E-cadherin significantly less in osteosarcoma with metastasis, and expression of both might be related to the prediction of metastasis potency and poor prognosis for patients with osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847601     DOI: 10.1007/s12032-012-0317-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 2.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

3.  Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.

Authors:  R Heimann; F Lan; R McBride; S Hellman
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

Review 4.  Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms.

Authors:  Qian Qin; Young Xu; Tao He; Chunlin Qin; Jianming Xu
Journal:  Cell Res       Date:  2011-08-30       Impact factor: 25.617

Review 5.  Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

Authors:  S Hirohashi
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

6.  Prognostic value of E-cadherin expression in 413 gastric carcinomas.

Authors:  H E Gabbert; W Mueller; A Schneiders; S Meier; R Moll; W Birchmeier; G Hommel
Journal:  Int J Cancer       Date:  1996-06-21       Impact factor: 7.396

7.  Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail.

Authors:  L Hao; J R Ha; P Kuzel; E Garcia; S Persad
Journal:  Br J Dermatol       Date:  2012-05-08       Impact factor: 9.302

8.  Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo.

Authors:  Takeshi Kashima; Kazuya Nakamura; Jitsutaro Kawaguchi; Masakatsu Takanashi; Tsuyoshi Ishida; Hiroyuki Aburatani; Akira Kudo; Masashi Fukayama; Agamemnon E Grigoriadis
Journal:  Int J Cancer       Date:  2003-03-20       Impact factor: 7.396

9.  An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.

Authors:  C T Shun; M S Wu; J T Lin; H P Wang; R L Houng; W J Lee; T H Wang; S M Chuang
Journal:  Hepatogastroenterology       Date:  1998 Jul-Aug

10.  Targeting invadopodia to block breast cancer metastasis.

Authors:  Mark A Eckert; Jing Yang
Journal:  Oncotarget       Date:  2011-07
View more
  23 in total

1.  Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma.

Authors:  Pengfei Lei; Dengfeng Ding; Jie Xie; Long Wang; Qiande Liao; Yihe Hu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Authors:  Jason A Somarelli; Samantha Shetler; Mohit K Jolly; Xueyang Wang; Suzanne Bartholf Dewitt; Alexander J Hish; Shivee Gilja; William C Eward; Kathryn E Ware; Herbert Levine; Andrew J Armstrong; Mariano A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2016-09-12       Impact factor: 4.272

3.  E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms.

Authors:  Mohit Kumar Jolly; Kathryn E Ware; Shengnan Xu; Shivee Gilja; Samantha Shetler; Yanjun Yang; Xueyang Wang; R Garland Austin; Daniella Runyambo; Alexander J Hish; Suzanne Bartholf DeWitt; Jason T George; R Timothy Kreulen; Mary-Keara Boss; Alexander L Lazarides; David L Kerr; Drew G Gerber; Dharshan Sivaraj; Andrew J Armstrong; Mark W Dewhirst; William C Eward; Herbert Levine; Jason A Somarelli
Journal:  Mol Cancer Res       Date:  2019-03-12       Impact factor: 5.852

4.  Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Authors:  Andressa Ardiani; Sofia R Gameiro; Claudia Palena; Duane H Hamilton; Anna Kwilas; Thomas H King; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

5.  High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma.

Authors:  Kojiro Ohba; Yasuyoshi Miyata; Tomohiro Matsuo; Akihiro Asai; Kensuke Mitsunari; Yohei Shida; Shigeru Kanda; Hideki Sakai
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

Review 6.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Junjiang Fu
Journal:  Tumour Biol       Date:  2014-06-02

7.  [Twist regulates proliferation, migration and invasion of osteosarcoma cells in vitro].

Authors:  Yun He; Shu-Yu Fang; Yang Bi; Tong-Chuan He; Yi Wang; Si-Qi Hong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

Review 8.  EMT transcription factors: implication in osteosarcoma.

Authors:  Guoqiong Yang; Jian Yuan; Kanghua Li
Journal:  Med Oncol       Date:  2013-08-24       Impact factor: 3.064

Review 9.  Research models and mesenchymal/epithelial plasticity of osteosarcoma.

Authors:  Xiaobin Yu; Jason T Yustein; Jianming Xu
Journal:  Cell Biosci       Date:  2021-05-22       Impact factor: 7.133

10.  SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Authors:  Branden A Smeester; Nicholas J Slipek; Emily J Pomeroy; Heather E Bomberger; Ghaidan A Shamsan; Joseph J Peterson; Margaret R Crosby; Garrett M Draper; Kelsie L Becklin; Eric P Rahrmann; James B McCarthy; David J Odde; David K Wood; David A Largaespada; Branden S Moriarity
Journal:  Oncogene       Date:  2019-10-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.